Meplazumab is under clinical development by Jiangsu Pacific Meinuoke Bio-Pharmarceutical and currently in Phase III for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID). According to GlobalData, Phase III drugs for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Meplazumab LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Meplazumab overview
Meplazumab is under development for the treatment of malaria and Coronavirus disease 2019 (COVID-19), post covid-19 and coronavirus disease 2019 (covid-19) pneumonia. Meplazumab, is a humanized immunoglobulin (Ig) G2 monoclonal antibody, consisting of the complementary-determining regions of anti CD147 murine antibody and the human framework region. It is administered through intravenous route. The therapeutic candidate acts by targeting extracellular matrix metalloproteinase inducer (EMMPRIN) or CD147.
Jiangsu Pacific Meinuoke Bio-Pharmarceutical overview
Jiangsu Pacific Meinuoke Bio-Pharmarceutical (Pacific Meinuoke) focuses on the development of novel biopharmaceuticals for addressing the unmet medical needs of patients with cancer and infectious diseases. Pacific Meinuoke is headquartered in Changzhou City, China.
For a complete picture of Meplazumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
